CLINICAL UPDATE · FOR HEALTHCARE PROFESSIONALS

Primary Care
Research Brief

11 September 2026

This was a “watch, not switch” week: important signals in COPD, menopause care, mental-health consultation mode and ureteric-stone treatment, but no finding that should override current local guidance in South Africa, the UK or Ireland.

PHASE 3 RANDOMISED TRIALS · CONFERENCE DATA

Tozorakimab may reduce COPD exacerbations across a broad population

Clinical question. Does adding the investigational anti-IL-33 monoclonal antibody tozorakimab to standard inhaled treatment reduce exacerbations in people with frequently exacerbating COPD?

Result. Detailed OBERON and TITANIA results presented at the European Respiratory Society Congress reported 29% to 34% fewer moderate or severe exacerbations over one year. Reported annualised rates were 1.41 and 1.44 with tozorakimab versus 2.00 and 2.03 with placebo, with broadly similar safety.

Evidence strength and limitations. The phase 3 randomised design and consistent results across two trials are encouraging. However, the figures available for this brief came from a conference report rather than a fully appraised primary publication; longer-term safety, absolute hospitalisation benefit, licensing, cost and real-world generalisability remain uncertain.

GP implication. Identify high-risk COPD patients by exacerbation history, adherence, inhaler technique, smoking exposure and pulmonary-rehabilitation needs. This drug is not yet a primary-care treatment option.

Practice verdict: Watch. Continue current GOLD, NICE and local COPD pathways; do not alter treatment until peer-reviewed appraisal, approval and commissioning decisions are available.

Read the ERS trial report →

TARGET-TRIAL EMULATION · PEER-REVIEWED OBSERVATIONAL EVIDENCE

Menopausal hormone therapy is still not cardiovascular prevention

Clinical question. Among symptomatic perimenopausal or recently postmenopausal women, is starting menopausal hormone therapy associated with cardiovascular risk?

Result. In 2,737 women with vasomotor symptoms followed for up to 20 years, 755 initiated systemic hormone therapy and 224 cardiovascular events occurred. Initiation was associated with fewer events overall (adjusted HR 0.78, 95% CI 0.62–0.98), with a stronger association when started within 10 years of menopause (aHR 0.73, 95% CI 0.58–0.93).

Evidence strength and limitations. The analysis used careful target-trial methods and a multiethnic longitudinal cohort, but it was not randomised. Nonfatal outcomes were self-reported, residual confounding is likely, and subgroup findings—including a larger apparent benefit in Black women—need replication.

GP implication. The findings are reassuring for appropriately selected symptomatic women starting treatment near menopause. Continue to individualise by symptoms, age, time since menopause, thromboembolic and breast-cancer risk, route and patient preference.

Practice verdict: Remain unchanged. Use hormone therapy for symptom relief where appropriate, not to prevent cardiovascular disease.

Read the study in JAMA Internal Medicine →

COMPARATIVE-EFFECTIVENESS COHORT · PEER-REVIEWED

Video mental-health care performed at least as well as phone or in-person care

Clinical question. Do outcomes differ when outpatient mental-health care is delivered mainly by video, phone or in person?

Result. Among 813,699 US Veterans, video care was associated with small absolute reductions in mental-health admission and emergency attendance and slightly fewer recorded suicidal behaviours. Expected admission risk was about 0.5 percentage points lower with video than with either phone or in-person care; appointment completion was 3.6 to 4.1 percentage points higher.

Evidence strength and limitations. This is a very large, adjusted real-world analysis, but modality was not randomised. Video users were healthier and better resourced, residual confounding remains plausible, and 83% of participants were men in a highly integrated US system.

GP implication. When remote mental-health follow-up is clinically safe and the patient has connectivity and privacy, video is a reasonable option. Do not infer that it is superior for every patient or replace in-person assessment when risk, safeguarding, diagnostic uncertainty or physical examination requires it.

Practice verdict: Watch and use selectively. Offer video as a practical modality, but preserve phone and face-to-face access to avoid widening digital inequity—particularly in resource-constrained settings.

Read the study in JAMA Network Open →

PHASE 3 RANDOMISED TRIAL · PEER-REVIEWED

A herbal extract increased passage of selected ureteric stones

Clinical question. Can Desmodium styracifolium total flavone capsules improve spontaneous passage of 5–10 mm ureteric stones?

Result. In a double-blind Chinese trial at 34 sites, 606 adults received the extract or placebo for 28 days. CT-confirmed passage occurred in 44.6% versus 33.8% (RR 1.32, 95% CI 1.03–1.69), an absolute difference of 10.9 percentage points and an approximate number needed to treat of nine. Adverse-event rates were similar.

Evidence strength and limitations. Randomisation, blinding and CT confirmation strengthen the result. The confidence interval was wide; there was no significant day-14 benefit; participants were all treated in China; background medication varied; and the tested standardised product is not routinely licensed or quality-assured in South Africa, the UK or Ireland.

GP implication. Do not substitute an unregulated supplement. Continue analgesia, hydration advice, appropriate alpha-blocker use under local guidance, safety-netting for infection or obstruction, and timely urology referral.

Practice verdict: Watch. Replication and regulatory-quality products are needed before routine use.

Read the randomised trial in JAMA Network Open →

MOST WORTH READING

Four selected sources

No eligible major NICE, Irish HSE or South African national primary-care guideline update was identified between 5 and 11 September 2026. Conference findings are labelled separately from peer-reviewed evidence. Educational summary for healthcare professionals; local guidance and individual clinical assessment take precedence.